Drug intelligence / Profile preview

GATE-252

Development stage: Preclinical
Lead developer: Gateway Biotechnology
Modality: Small Molecules
Administration: Oral

Overview

**GATE-252** is a preclinical, orally administered small-molecule N-methyl-D-aspartate receptor modulator originated by Gate Neurosciences for cognitive disorders. It is described as a fourth-generation synaptic-function program intended to modulate N-methyl-D-aspartate receptor signaling and support synaptic function in central nervous system disease. No international nonproprietary name, chemical structure, precise receptor binding site, functional pharmacology, dosage form, manufacturer, or clinical-trial record has been publicly identified.

Targets

NMDAR (Glutamate receptor ionotropic, NMDA)

Beyond the preview

Go deeper on GATE-252.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GATE-252.

Explore the full profile